RXRX: Recursion Pharmaceuticals Inc Company Sales Revenue

Aggressive hiring of Deep Learning specialists and bioinformaticians ensures Recursion Pharmaceuticals (RXRX) maintains its R&D leadership. The company dictates pricing power to Big Pharma thanks to its unique AI biology map. The company's sales volume dynamics in the GURU.Markets terminal contain a parameter that has settled at 0.07. Silicon Valley visionaries, attracted by stock options and the digitalization of medicine, support the project's success.

RXRX (Recursion Corp) Revenue and Sales Volume history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Recursion Pharmaceuticals

- current price and projected stock value:

Share Price recursion.com|RXRX - Consensus Target

- market capitalization information:

Market Value Recursion Pharmaceuticals, Inc.|RXRX - Total Company Value

- balance sheet net asset value indicators:

Share Book Value Recursion|RXRX - Book Capitalization|Market Value to Book Value recursion.com|RXRX - Company Total Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

RXRX - Net Profit|Expected Net Profit Recursion Pharmaceuticals|RXRX - Price to Earnings Ratio|Forward P/E Multiple Recursion Pharmaceuticals|RXRX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Recursion Pharmaceuticals, Inc.|RXRX - Operating profit EBITDA|Net earnings per share for the last four quarters Recursion|RXRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months recursion.com|RXRX - Earnings growth in current year|Earnings growth forecast for next year Recursion Pharmaceuticals

- company sales and revenue statistics:

RXRX - Company Revenue|Company Projected Revenue Recursion Pharmaceuticals, Inc.|RXRX - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Recursion Pharmaceuticals, Inc.

Comprehensive company analysis:RXRX Recursion Corp

Core merchandise of Recursion Pharmaceuticals, Inc.

This metric measures total cash inflow from core operations, allowing for an assessment of the real purchasing power of revenue adjusted for inflationary pressure. By analyzing the product sales revenue of Recursion Pharmaceuticals (RXRX), an investor can confirm the operational resilience of Recursion Pharmaceuticals through the growth of milestone payments from NVIDIA and Roche, which validates the commercial viability of their AI models.

Key competitors